Literature DB >> 34035481

Pushing the envelope with PCSK9.

Katie Kingwell.   

Abstract

Entities:  

Year:  2021        PMID: 34035481     DOI: 10.1038/d41573-021-00093-9

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  An oral antisense oligonucleotide for PCSK9 inhibition.

Authors:  Peter Gennemark; Katrin Walter; Niclas Clemmensen; Dinko Rekić; Catarina A M Nilsson; Jane Knöchel; Mikko Hölttä; Linda Wernevik; Birgitta Rosengren; Dorota Kakol-Palm; Yanfeng Wang; Rosie Z Yu; Richard S Geary; Stan J Riney; Brett P Monia; Rikard Isaksson; Rasmus Jansson-Löfmark; Cristina S J Rocha; Daniel Lindén; Eva Hurt-Camejo; Rosanne Crooke; Lloyd Tillman; Tina Rydén-Bergsten; Björn Carlsson; Ulf Andersson; Marie Elebring; Anna Tivesten; Nigel Davies
Journal:  Sci Transl Med       Date:  2021-05-12       Impact factor: 17.956

2.  In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.

Authors:  Kiran Musunuru; Alexandra C Chadwick; Taiji Mizoguchi; Sara P Garcia; Jamie E DeNizio; Caroline W Reiss; Kui Wang; Sowmya Iyer; Chaitali Dutta; Victoria Clendaniel; Michael Amaonye; Aaron Beach; Kathleen Berth; Souvik Biswas; Maurine C Braun; Huei-Mei Chen; Thomas V Colace; John D Ganey; Soumyashree A Gangopadhyay; Ryan Garrity; Lisa N Kasiewicz; Jennifer Lavoie; James A Madsen; Yuri Matsumoto; Anne Marie Mazzola; Yusuf S Nasrullah; Joseph Nneji; Huilan Ren; Athul Sanjeev; Madeleine Shay; Mary R Stahley; Steven H Y Fan; Ying K Tam; Nicole M Gaudelli; Giuseppe Ciaramella; Leslie E Stolz; Padma Malyala; Christopher J Cheng; Kallanthottathil G Rajeev; Ellen Rohde; Andrew M Bellinger; Sekar Kathiresan
Journal:  Nature       Date:  2021-05-19       Impact factor: 69.504

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.